Slideshow

Precautions for Medical Cannabis in Rheumatology

To help clinicians provide guidance to patients interested in cannabis therapies, the Canadian Rheumatology Association has issued a position statement. In this slideshow, we highlight the recommendations.

Patient interest in medical cannabis treatments has increased in recent years. However, no studies analyzing the use and impact of cannabis in rheumatology patients exist. To help clinicians provide beneficial guidance to patients interested in cannabis therapies, the Canadian Rheumatology Association has issued a position statement. In this slideshow, we highlight the recommendations.For more information on the position statement, see:  “What’s a physician to do in the absence of clinical guidelines for cannabis?”

References:

Fitzcharles MA, Zahedi NO, Hauser W, Hazelwood G, the Canadian Rheumatology Association. “Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.” Journal of Rheumatology. (2019), DOI: 10.3899/rheum.181120.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.